Celecoxib Inhibitor CAS No. 169590-42-5

Cat. No.	Name	Size	Price	Add Cart
KI0305	Celecoxib	100 mg	$180
KI0305	Celecoxib	1 g	$490

Chemical Characteristic

Product Name	Celecoxib
Synonyms	Celebrex
CAS No.	169590-42-5
Molecular Weight	381.37
Formula	C₁₇H₁₄F₃N₃O₂S
Chemical Name	4-[5-(4-Methylphenyl)-3-trifluoromethyl)-1H-pyrazol-yl]benzenesulfonamide
Smiles	c1(ccc(cc1)n1nc(cc1c1ccc(cc1)C)C(F)(F)F)S(=O)(=O)N
Chemical Structure

Biological activities

Celecoxib is a sulfa non-steroidal anti-inflammatory drug and selective COX-2 inhibitor with an IC50 of 40 nM. ED_{50s of celecoxib are 0.37, 7.1 and 34.5 mg/kg in rat adjuvant-induced arthritis assay, carrageenan-induced foot pad edema assay and carrageenan-induced hyperalgesia assay.^[1] The IC50 for celecoxib for inhibition of LLC cells is 40 μM. When celecoxib concentrations of ??0 μM are used, no cytotoxicity effect on LLC cells viability or growth is observed. When celecoxib concentrations of ??0 μM are used, a dramatic decrease in cell viability is observed. Furthermore, 50 μM celecoxib treatment causes significant apoptosis in all three cell lines with 88%, 37%, and 15% of LLC, HCA-7, and HCT-15 cells, respectively, undergoing apoptosis.^[2] Celecoxib has similar in vitro antiproliferative effects on both epithelial and hematopoietic cancer cell lines, with IC50 values ranging from 35 to 65 μM. When dose-response effects of rofecoxib and celecoxib are compared between the COX-2 epithelial line A549, and the COX-2-negative, hematopoietic line BALL-1, celecoxib exposure results in growth inhibition ??0% in both lines, whereas rofecoxib exposure results in ??0% inhibition over the entire concentration range (0-60 μM). At the 135 μM concentration of celecoxib and rofecoxib, the percentages of Annexin V??cells are 43.4 and 7.2, respectively, for the A549 cell line and 60.7 and 8.2 for the BALL-1 cell line.^[3] IC50 dose of celecoxib (70 μM for HuH7 cells and 61 μM for PLC cells) significantly decreases proliferating cell nuclear antigen expression (75.8% in HuH7 cells and 45.0% in PLC cells) by western blot analysis. IC50 dose of celecoxib (70 μM for HuH7 cells and 61 μM for PLC cells) also results in significant time-dependent inhibition of cell proliferation in both HuH7 cells and PLC cells that is associated with a comparable pattern of decreased BrdUrd uptake.^[4] In HCA-7 xenograft model, celecoxib (1250 mg/kg of chow) significantly prevents the growth of colorectal carcinoma cells HCA-7 xenograft when compared with animals on the control diet.^[2] In vivo HuH7 xenografts in nude mice, celecoxib (50 mg/kg/day) is associated with a significantly reduced PGE2 production in hepatocellular carcinoma xenograft tissue, indicating an in vivo COX-2-dependent pathway, and celecoxib (50 mg/kg/day) increases PPARγ expression in the xenograft tissue, indicating an in vivo mechanism of the COX-2-independent pathway.^[4]}

Protocols

Celecoxib is dissolved initially in DMSO. ^[3]

References

[1] Penning TD, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl) -1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997, 40(9): 1347-1365. [2] Williams CS, et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 2000, 60(21): 6045-6051. [3] Waskewich C, et al. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 2002, 62(7): 2029-2033. [4] Cui W, et al. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res. 2005, 11(22): 8213-8221.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.

KareBay^TM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.

About

KareBay^TM Biochem
Sitemap
Blog

Custom Services

Organic Synthesis
Peptide Synthesis
Antibody Production
Protein Expression
Bioconjugation Service
Immunoassry Service
Molecular Biology Services
Oligonucleotides Synthesis
RNA Synthesis Service
cGMP Peptide Synthesis Services
cGMP Organic Synthesis Services

Biochemical Products

Small Molecule Inhibitors
Bioactive Compounds
Primary Antibodies
Peptides
Amino Acids
Reagents
Fluorescent dyes
Intermediates
PCR

KareBay^TM Biochem, Inc.
11 Deer Park Drive, Suite 102A
Monmouth Junction, NJ 08852

Telephone

: 732-823-1545

Fax

: 732-823-1349

product@karebaybio.com
service@karebaybio.com
support@karebaybio.com